Key TakeawaysTesla shares hit another record high Tuesday before edging lower. The stock has surged since the presidential election on optimism that Tesla will benefit from Musk's ties to President-elect Donald Trump, aiding several of its efforts.Mizuho analysts said Tesla could see tailwinds under the Trump administration, such as looser regulations around autonomous driving. Tesla (TSLA) shares hit a second record high in as many days Tuesday after another analyst upgraded their rating of the electric ve ...

Group 1 - Pfizer affirmed its full-year 2024 projections, expecting revenue between $61 billion and $64 billion for both 2024 and 2025, with adjusted earnings per share (EPS) projected to grow in 2025 [1][2][3] - For 2024, adjusted EPS is projected to be between $2.75 and $2.95, aligning with analyst estimates of $63.01 billion in revenue and $2.93 EPS [2][3] - Pfizer successfully met its cost-cutting goal of $4 billion by the end of 2024, with an additional $500 million in savings expected over the next year [4][5] Group 2 - Pfizer's shares rose by 4.5% following the announcement, although they remain down approximately 8% for the year [6] - The company has returned to year-over-year revenue growth in its two most recent quarters for the first time since the peak of COVID vaccine sales [1][4]

Group 1 - EVgo's largest investor, EVgo Holdings, plans to sell 23 million shares of Class A common stock and offers underwriters a 30-day option to buy an additional 3.45 million shares [1] - EVgo will not receive any proceeds from the sale, which will entirely benefit LS Power, the majority owner of EVgo's voting stock [1] - LS Power's significant holdings allow it to influence key corporate decisions, including director elections and major transactions [1] Group 2 - EVgo recently closed on a $1.25 billion loan guarantee from the Department of Energy to install 7,000 EV chargers over the next five years [2] - The company warned that failing to meet loan conditions could materially and adversely affect its business, leading to a drop in share prices [2] - Despite a 25% loss shortly after the announcement, EVgo's shares have increased by approximately 30% in 2024 [2]

Core Insights - Tesla shares have reached a new record high following an upgrade from Wedbush, which raised its price target from $400 to $515, with a potential high of $650 by the end of next year due to anticipated support from the incoming Trump administration for Tesla's self-driving and AI initiatives [2][3] Group 1: Stock Performance - Tesla shares have surged approximately 85% since the beginning of the year, with significant gains occurring post-election due to optimism surrounding CEO Elon Musk's relationship with President-elect Donald Trump [3] - The stock gained 6% in regular trading and an additional 2% in extended hours, trading around $472 [4] Group 2: Technical Analysis - The stock has trended sharply higher after breaking out from an ascending triangle, with increasing trading volumes supporting the rally [5] - Bars pattern analysis projects a bullish target of around $510, where investors may consider locking in profits [8] - Key support levels to monitor include $360, $300, and $265, which may provide buying opportunities during potential pullbacks [9][10]

Market Overview - The S&P 500 increased by 0.4% on December 16, driven by gains in technology stocks ahead of the Federal Reserve's interest-rate announcement [1][2] - Major U.S. equity indexes showed mixed performance as traders anticipated a potential reduction in borrowing costs by the Federal Reserve [2][3] Company Highlights - Broadcom's stock surged by 11.2% following a strong quarterly earnings report, highlighting robust AI sales, and was named a top semiconductor pick by Bernstein analysts [4] - Tesla's shares rose by 6.1% to an all-time high, with analysts estimating the potential value of its full self-driving and AI technology at $1 trillion [5] - Micron Technology's stock jumped 5.6% ahead of its quarterly results, with expectations of strong year-over-year growth and recent federal grants of approximately $6 billion under the CHIPS Act [6] - Super Micro Computer's shares fell by 8.3% after being removed from the Nasdaq 100 and reports of a potential capital raise [7] - CVS Health's shares declined by 5.6% following comments from President-elect Donald Trump regarding the elimination of middlemen in prescription drug pricing [8] Sector Performance - The communication and technology sectors contributed to a 1.2% gain for the Nasdaq, which reached a record closing high [3] - Crude oil prices decreased due to disappointing consumer spending data from China, impacting oil and gas stocks, with Phillips 66 and Marathon Petroleum shares falling by 5.2% and 5.1%, respectively [9]

Key TakeawaysNvidia stock has entered correction territory, which occurs when shares fall 10% from their peak.Despite the recent slide, analysts remain bullish on the chipmaking giant long term.The company's stock took a slight hit last week after Chinese regulators said they would investigate the company for potential violations of anti-monopoly laws. Nvidia (NVDA) stock slipped into correction territory Monday, but analysts are still bullish on the chipmaking giant.  Nvidia shares fell 2% intraday Monday ...

Core Insights - Ford Motor's stock was downgraded by Jefferies from "hold" to "underperform," with a price target reduction from $12 to $9, which is below Wall Street's consensus [1][2] - The downgrade is attributed to concerns over an increasing inventory backlog and costs related to restructuring and warranty payments [1][2] - Ford's inventory has risen to 96 days despite solid sales, indicating a need for "de-stocking" [2] Inventory and Financial Health - Analysts noted that Ford's balance sheet is "robust rather than strong," suggesting potential financial strain due to restructuring and warranty claims [2] - The company faces challenges in maintaining cash for shareholders while aiming for a conservative financial profile [2] Market Performance - Year-to-date, Ford's shares have declined approximately 18%, while General Motors' shares have increased by about 40% [2]

Key TakeawaysAccenture is expected to report first-quarter fiscal 2025 results before the opening bell Thursday.Analysts expect revenue and net income to have climbed year-over-year.Last quarter, new generative AI bookings reached $1 billion. Accenture (ACN) will report first-quarter fiscal 2025 earnings before the opening bell Thursday, and analysts see room for growth ahead of the results. Of the 13 brokers covering the stock tracked by Visible Alpha, nine have a "buy" or equivalent rating, compared to fo ...

Group 1 - Oppenheimer raised Netflix's price target to $1,065 from $825, the highest among analysts tracked by Visible Alpha, citing the benefits of live events [1][2] - The analysts maintained an "outperform" rating on Netflix, expecting positive commentary from upcoming NFL Christmas Day games to drive sentiment into Q4 earnings [1] - JPMorgan also increased its price target for Netflix to $1,010 from $850, highlighting the impact of programming such as the Jake Paul/Mike Tyson boxing match [2] Group 2 - Oppenheimer noted that Netflix is "the only investable mainstream media stock" due to weakening competition and low churn rates, which enhance content cost leverage [2] - Analysts pointed out potential for subscriber expansion beyond 500 million households globally, driven by Netflix's live event offerings [2] - Netflix shares reached an all-time high last week and have increased nearly 90% this year [2]

Group 1 - Palantir Technologies shares fell approximately 4% on Monday, while MicroStrategy shares rose by 4% following the announcement that both companies will be added to the Nasdaq 100 Index on December 23 [1][2][3] - Axon Enterprise will also join the Nasdaq 100 Index, replacing Super Micro Computer, Moderna, and Illumina [1][2] - The Nasdaq 100 Index consists of the 100 largest non-financial sector companies in the Nasdaq Composite Index and is reconstituted annually [1][3] Group 2 - Super Micro Computer's stock dropped nearly 7%, and it faces potential delisting from the Nasdaq if it fails to file its delayed annual report by February [4] - Moderna's shares increased by less than 1%, while Illumina's shares rose by 1.5% [3]